يعرض 1 - 20 نتائج من 30,456 نتيجة بحث عن '(( a larger decrease ) OR ((( a ((non decrease) OR (_ decrease)) ) OR ( _ largest decrease ))))', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

    منشور في 2025
    "…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …"
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. حسب Mieke L. M. Bentvelzen (21594442)

    منشور في 2025
    "…<p><b>(A)</b> Manhattan plot of minJSW decrease at 24 months. …"
  16. 16

    Does a correlation exist between delayed vaccination and a decreased vaccine confidence? حسب Virginia Reverte (9046494)

    منشور في 2024
    "…Online questionnaire was sent to their parents, followed by a telephone questionnaire for non-responders. Regarding MMR first dose, a significant association was found between delay and birth order and intellectual/motor delay of children. …"
  17. 17

    Intent to decrease use of OTC NSAIDs and NSAID exposure. حسب Matthew G. Vinson (22593374)

    منشور في 2025
    "…<p>(A) Scatter plot of the group effect on intent to decrease use of OTC NSAIDs at pre-intervention and post-intervention. …"
  18. 18

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

    منشور في 2025
    "…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
  19. 19
  20. 20